Navigation Links
Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease,Presented at International Congress of Parkinson's Disease and,Movement Disorders

ra to confirm that amantadine, originally developed as an antiviral and now commonly used to address side effects of L-dopa therapy, could help Parkinson's patients.

"The differentiated profile observed in this Phase II trial is interesting and intriguing as there are currently no other drugs with this combination of therapeutic effects," said Professor Rascol. "Particularly if the therapeutic effect on non-levodopa sensitive symptoms can be confirmed in the Phase IIb and subsequent trials, the compound would address a very important unmet medical need for all mid-to-late stage patients developing postural disturbances, and could represent a significant advance in approaches to Parkinson's disease."

Also being presented at the conference is a poster on the results of FP0011 in a MPTP macaque monkey model of Parkinson's disease, by Dr. Jonathan Brotchie, CEO of Atuka Ltd. of Toronto, Canada. In this trial, monkeys that have developed dyskinesia from the administration of L-dopa to treat Parkinsonian symptoms from the neurotoxin, MPTP, were administered FP0011. FP0011 reduced the severity of L-dopa-induced dyskinesia while extending the duration of the anti-Parkinsonian action of L-dopa.

"Unlike other drugs on the market that increase the duration of L-dopa action, FP0011 did not exacerbate the problem of dyskinesia," said Dr. Brotchie. "If these effects were seen in patients, then over the course of a day such an action could significantly enhance the quality of life of people with advanced Parkinson's disease."

Commenting on these presentations, Thomas Seoh, CEO of Faust noted that: "These mutually supportive data in the Phase IIa trial and the MPTP monkey trial presented at this conference strongly support the further clinical development of FP0011 as an adjunctive therapy to L-dopa in patients with established motor complications. We look forward to confirming and extending these results in larger trials for Parkinson's patients. Ultima
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/2/2008)...ire/ -- Horizon Therapeutics, Inc., a,privately h...t two pivotal,Phase 3 trials evaluating its lead ...ll primary endpoints. HZT-501, a novel, proprietar...ofen and famotidine, demonstrated a,statistically...roidal,anti-inflammatory drug (NSAID)-induced upp...
(Date:12/1/2008)...c. 2 A study has found ...chnique for imaging the breast, is not affected by...s, two factors that limit the effectiveness of sta...ults will be presented today at the annual meeting...A). , , "The ability of PEM to detect canc...
(Date:12/1/2008).../ -- S*BIO Pte Ltd today announced the initiation ...and orally-active JAK2 inhibitor, in leading medic...idiopathic myelofibrosis (CIMF). , , The t...bility of SB1518 in patients with CIMF and is expe... of the study will assess the safety profile and e...
(Date:12/1/2008)...1 gene is a two-way switch that, if turned off, ca...d so that they lose their identity and become more...Tenn., Dec. 1 Scientis...iscovered that a certain differentiated cell type ...s the constant expression of a gene called Prox1 ...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 1Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 1SI International Awarded 244 Million Army HRsolutions Task Order 3781 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 3Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 1Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 1CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 3CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 4
...oequivalent Pharmacokinetics With Reduced Risk,of ..., April 25, 2007 /PRNewswire-FirstCall/ -- ADVENTR...arch and,development company focused on commercial...ment of cancer and infectious diseases,today anno...netic,testing of ANX-514 (docetaxel emulsion) in a...
..., April 25, 2007 - Basilea Pharmaceutica Ltd.,(SWX...ing that,patients with severe chronic hand eczema ...n two previous randomized clinical,trials, alitret...,chronic hand eczema in patients refractory to top...hat patients responsive to initial,treatment with ...
Other Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
(Date:12/2/2008)... 2 MedPro Imaging, a premier provi...ounced the appointment of three,new ultrasound sa...ressive,expansion. The company also announced th...ties due to substantial growth throughout 2008. K...esident of Sales and Marketing in,February of thi...
(Date:12/2/2008)...ford researchers has developed a prototype blood s...ream in early stages of the disease, potentially a...roved chances of survival. , The system based on...iated proteins in a blood serum sample in less tha...existing commercial devices. In fact, the device, ...
(Date:12/2/2008)...ewswire/ -- MedCommons announces integration of it...rchive Solution for Healthcare,Organizations. The...,Organizations provides a modular DICOM-compliant ...s patient information, including medical images fr...ent-centric archive. The,integration with the Med...
(Date:12/2/2008)...with FDA in Early to Mid-2009 , , WARREN, N...ers of PharmFilm(R) technology and a drug delivery...maceutical products, and Strativa Pharmaceuticals,...utical Companies, Inc. (NYSE: PRX ), today annou...quivalence studies for a thin film formulation of ...
Breaking Medicine News(10 mins):Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2Health News:Stanford blood scanner detects even faint indicators of cancer 2Health News:Stanford blood scanner detects even faint indicators of cancer 3Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 3Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3
...uses genetic damage// in the developing fetus, say...ing during pregnancy causes genetic damage in the ...ephen G. Grant, Ph.D., associate professor of envi...health in the University of Pittsburgh Graduate Sc...
... by illnesses due to exposure to //pesticides have... to 2002, reports a research in the recent issue o...ronment is a health risk facing children and schoo...n the article states. Pesticides continue to be us...
...on (IMA) has today warned its members// all over t... dealing with patients who suffer from bullet, kni...oist violence taking place in the neighboring coun...affarpur district was arrested in May for treating...
...be used successfully to treat heart attacks//. Res...edicine had showed that it is possible to treat th...wo months, stem cells harvested from another pig?s...mal?s damaged heart restored heart function and re...
Other Medicine News:Health News:Exposure to Pesticides in Schools Produces Illnesses Among Employees, Students 2Health News:Stem Cell Therapy For Treating Heart Attacks 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: